Latest Ratings for NBIX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Piper Sandler | Downgrades | Overweight | Neutral |
| Feb 2022 | Goldman Sachs | Upgrades | Neutral | Buy |
| Feb 2022 | Morgan Stanley | Maintains | Equal-Weight |
Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
